Nov,2023. Jiangxi Ashter Pharmaceutical Co Ltd, branch company of Jemincare, get the drug registration licence for Palbociclib Capsules 75mg, 100mg and 150mg for the treatment of breast cancer. Palbociclib API of Jemincare group get the licence in Nov, 2023 as well.
Palbociclib is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. More than 1.3 million women worldwide are diagnosed with breast cancer each year, making it the second most common cancer after lung cancer, with estrogen receptor-positive (ER+) breast cancer being the most common breast cancer subtype. Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy forthe treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer in postmenopausal women who have not received systemic therapy.
Palbociclib is approved for marketing in 2015. It was approved to enter the Chinese market in 2018. It is currently on the market in more than 80 countries around the world. It has long occupied the majority of the market share of CDK inhibitors in the United States. In 2022, it will be the global Sales reached $5.12 billion. The patent on the palbociclib compound expires on January 10, 2023.
About Jemincare
Founded in 1999 in Nanchang, Jemincare now has more than 12,000 employees and its revenue has surpassed RMB 41 billion in 2021. As an international group, Jemincare mainly engages in medical care, clean energy, mineral development and industrial investment to promote human health and sustainable development through innovation.[2]https://www.jmkx.com/LanguageVersion/English/group_eng.aspx
